

Långtidseffekter av ATMP

Fråga

Vilken sammanställd forskning finns om långtidseffekter av ATMP?

Frågeställare: Tandvårds- och läkemedelsförmånsverket

Bakgrund

Advanced Therapy Medicinal Products (ATMP) är biologiska läkemedel som baseras på gener, celler eller vävnader. Tandvårds- och läkemedelsförmånsverket (TLV) har fått ett regeringsuppdrag att fortsätta det arbete med att utveckla metoder för hälsoekonomiska utvärderingar av precisionsmedicin och betalningsmodeller för avancerade terapiläkemedel (ATMP) som myndigheten har påbörjat. För detta arbete krävs information om de aktuella produkternas effektduration.

Frågeställning och avgränsningar

Upplysningstjänsten har tillsammans med frågeställaren formulerat frågan enligt följande PICO¹:

- **Population:** Patienter med hematologiska cancersjukdomar; patienter med ärftliga/genetiska sjukdomar (diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL), inherited retinal dystrophy, B-cell acute lymphoblastic leukaemia (ALL), beta-Thalassemia, spinal muscular atrophy (SMA), metachromatic leukodystrophy (MLD), multiple myeloma, mantle cell lymphoma, lymphoblastic leukaemia, haemophilia A, severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), aromatic L-amino acid decarboxylase (AADC) deficiency, haemophilia B, Hyperlipoproteinemia Type I, melanoma, Leber's hereditary optic neuropathy)
- **Intervention:** Namngivna ATMP (Yescarta, Luxturna, Kymriah, Zynteglo, Zolgensma, Libmeldy, Abecma, Tecartus, Roctavian, Strimvelis, Carvykti, Upstaza, Breyanzi, EtranaDez, Glybera, Imlygic, Lumevoq)
- **Control:** Med eller utan kontroll
- **Outcome:** Effekt över tid, varaktighet. Utfall som indikerar att effekten är kvarstående eller avtagande.
- **Övriga kriterier:** Sökningen begränsas till år 2018 och framåt. Endast systematiska översikter och HTA-rapporter inkluderas.

Upplysningstjänsten har gjort sökningar (se Bilaga 1) i databasen Embase samt i INAHTA²:s databas för HTA³-rapporter. Vi har även sökt utifrån utvalda sökord i bilaga 1 på hemsidor för HTA-organisationer (NICE, NIHR, CADTH, KCE, IQWiG, AHRQ, FHI) [1-7].

Resultat från sökningen

Upplysningstjänstens litteratursökning i Embase genererade totalt 575 artikelsammanfattningar (abstrakt) efter dubblettkontroll. Två utredare på SBU läste alla artikelsammanfattningar och bedömde att 61 översikter kunde vara relevanta för frågan baserat på intervention och publikationstyp [8-68]. Dessa artiklar presenteras i Bilaga 2. Observera att artiklarna inte har lästs i fulltext. Flera av artiklarna i Bilaga 2 kan därför utgöras av översikter som vi efter fulltextläsning inte skulle ha bedömt som systematiska eller vara av en lägre kvalitet (ha en högre risk för bias) än vad vi normalt inkluderar i svar från Upplysningstjänsten [69]. Sökningen i INAHTA:s databas genererade 46 träffar vilka alla inkluderades i svaret utan

¹ PICO är en förkortning för patient/population/problem, intervention/index test, comparison/control (jämförelseintervention) och outcome (utfallsmått).

² International Network of Agencies for Health Technology Assessment (INAHTA)

³ Utvärdering av hälso- och sjukvårdens (och i SBU:s fall socialtjänstens) metoder (eng. Health Technology Assessment)

granskning [70-115]. Handsökningen på hemsidor för HTA-organisationer resulterade i elva unika rapporter från CADTH som inte fångats av sökningen i INAHTA:s databas [116-126].

SBU har på uppdrag av Socialstyrelsen tagit fram ett vetenskapligt underlag där det ingår en systematisk sökning och sammanställning av effekten för Onasemnogene (Zolgensma) vid spinal muskelatrofi [127].

Projektgrupp

Detta svar är sammanställt av Idha Kurtsdotter (utredare), Carl Gornitzki (utredare/informationsspecialist), Irene Edebert (produktionsordnare) samt Pernilla Östlund (avdelningschef) vid SBU.

Bilagor

- Bilaga 1 – Litteratursökning
- Bilaga 2 – Tabell med inkluderade referenser
- Bilaga 3 – Flödesschema

Referenser

1. Folkhelseinstituttet (FHI). Bergen: Folkhelseinstituttet. [accessed Jan 20 2023]. Available from: <https://www.fhi.no/>.
2. National Institute for Health and Care Excellence (NICE). London: National Institute for Health and Care Excellence. [Available from: <https://www.nice.org.uk/>].
3. Canadian Agency for Drugs and Technologies in Health (CADTH). Ottawa: Canadian Agency for Drugs and Technologies in Health. [Available from: <https://www.cadth.ca/>].
4. National Institute for Health and Care Research (NIHR). National Institute for Health and Care Research. [Available from: <https://www.nihr.ac.uk/>].
5. Belgian Health Care Knowledge Centre (KCE). Belgian Health Care Knowledge Centre. [Available from: <https://kce.fgov.be/en>].
6. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. [Available from: <https://www.iqwig.de/en/>].
7. Agency for Healthcare Research and Quality (AHRQ). Rockville: Agency for Healthcare Research and Quality. [Available from: <https://www.ahrq.gov/>].
8. Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Clin Lymphoma Myeloma Leuk. 2021;21(4):e334-e47. Available from: <https://doi.org/10.1016/j.clml.2020.12.010>.
9. Al-Mansour M, Al-Foheidi M, Ibrahim E. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis. Mol Clin Oncol. 2020;13(4):33. Available from: <https://doi.org/10.3892/mco.2020.2103>.
10. Anderson MK, Torosyan A, Halford Z. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. Ann Pharmacother. 2022;56(5):609-19. Available from: <https://doi.org/10.1177/10600280211026338>.
11. Baranello G, Gorni K, Daigl M, Kotzeva A, Evans R, Hawkins N, et al. Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy. Clin Pharmacol Ther. 2021;110(6):1435-54. Available from: <https://doi.org/10.1002/cpt.2247>.

12. Bhatt DK, Wekema L, Carvalho Barros LR, Chammas R, Daemen T. A systematic analysis on the clinical safety and efficacy of onco-virotherapy. *Mol Ther Oncolytics*. 2021;23:239-53. Available from: <https://doi.org/10.1016/j.omto.2021.09.008>.
13. Britten-Jones AC, Jin R, Gocuk SA, Cichello E, O'Hare F, Hickey DG, et al. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review. *Genet Med*. 2022;24(3):521-34. Available from: <https://doi.org/10.1016/j.gim.2021.10.013>.
14. Burgess FR, Hall HN, Megaw R. Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease. *Asia Pac J Ophthalmol (Phila)*. 2022;11(4):380-91. Available from: <https://doi.org/10.1097/APO.0000000000000545>.
15. Böhnke A, Minartz C, Radeck-Knorre S, Schwenke C, Neubauer AS. Gene therapy for rare diseases: Differences to chronic therapy and example AADC-deficiency. *Gentherapie für seltene Erkrankungen: Unterschiede zu chronischer Therapie und Beispiel AADC-Mangel*. 2022;27(1):25-35. Available from: <https://doi.org/10.1055/a-1629-7213>.
16. Cao JX, Gao WJ, You J, Wu LH, Liu JL, Wang ZX. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. *Cytotherapy*. 2019;21(7):769-81. Available from: <https://doi.org/10.1016/j.jcyt.2019.04.005>.
17. Chen Z, Cheng Y, DeRemer D, Diaby V. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. *Expert Rev Pharmacoecon Outcomes Res*. 2021;21(5):923-41. Available from: <https://doi.org/10.1080/14737167.2021.1913056>.
18. Cook M, Chauhan A. Clinical Application of Oncolytic Viruses: A Systematic Review. *Int J Mol Sci*. 2020;21(20):1-36. Available from: <https://doi.org/10.3390/ijms21207505>.
19. Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, et al. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. *Curr Med Res Opin*. 2022;38(10):1759-67. Available from: <https://doi.org/10.1080/03007995.2022.2100651>.
20. Dangouloff T, Botty C, Beaudart C, Servais L, Hilgsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. *Orphanet J Rare Dis*. 2021;16(1):47. Available from: <https://doi.org/10.1186/s13023-021-01695-7>.
21. Efficace F, Cannella L, Sparano F, Giesinger JM, Vignetti M, Baron F, et al. Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. *Hemasphere*. 2022;6(12):e802. Available from: <https://doi.org/10.1097/HS9.0000000000000802>.
22. Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. *Eur J Paediatr Neurol*. 2022;39:1-10. Available from: <https://doi.org/10.1016/j.ejpn.2022.04.006>.
23. Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, et al. Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal. *Pharmacoeconomics*. 2020;38(12):1309-18. Available from: <https://doi.org/10.1007/s40273-020-00953-z>.
24. Gao P, Ding G, Wang L. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. *Transl Cancer Res*. 2021;10(10):4290-302. Available from: <https://doi.org/10.21037/tcr-21-905>.
25. George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, et al. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. *Clin Lymphoma Myeloma Leuk*. 2021;21(11):741-51. Available from: <https://doi.org/10.1016/j.clml.2021.06.003>.
26. Gye A, Goodall S, De Abreu Lourenco R. A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. *Value Health*. 2022;25(1):47-58. Available from: <https://doi.org/10.1016/j.jval.2021.07.008>.
27. Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. *J Am Acad Dermatol*. 2020;83(1):189-96. Available from: <https://doi.org/10.1016/j.jaad.2020.01.039>.
28. Halford Z, Anderson MK, Bennett LL. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. *Ann Pharmacother*. 2021;55(3):390-405. Available from: <https://doi.org/10.1177/1060028020944233>.

29. Halford Z, Anderson MK, Bennett LL, Moody J. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. *Ann Pharmacother*. 2021;55(4):466-79. Available from: <https://doi.org/10.1177/1060028020948165>.
30. Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, et al. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. *Hemasphere*. 2021;5(2):e524. Available from: <https://doi.org/10.1097/HS9.0000000000000524>.
31. Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, et al. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. *Pharmacoeconomics*. 2021;39(9):995-1019. Available from: <https://doi.org/10.1007/s40273-021-01051-4>.
32. Horton RH, Saade D, Markati T, Harriss E, Bonnemann CG, Muntoni F, et al. A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment. *J Neurol Neurosurg Psychiatry*. 2022;93(12):1276-88. Available from: <https://doi.org/10.1136/jnnp-2022-329431>.
33. Lalu M, Leung GJ, Dong YY, Montroy J, Butler C, Auer RC, et al. Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review. *BMJ Open*. 2019;9(12):e029475. Available from: <https://doi.org/10.1136/bmjopen-2019-029475>.
34. Leroy BP, Fischer MD, Flannery JG, MacLaren RE, Dalkara D, Scholl HPN, et al. Gene therapy for inherited retinal disease: long-term durability of effect. *Ophthalmic Res*. 2022. Available from: <https://doi.org/10.1159/000526317>.
35. Li J, Tang Y, Huang Z. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials. *Transl Cancer Res*. 2022;11(3):569-79. Available from: <https://doi.org/10.21037/tcr-22-344>.
36. Li Z, Jiang Z, Zhang Y, Huang X, Liu Q. Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2020;12(6). Available from: <https://doi.org/10.3390/cancers12061416>.
37. Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. *Br J Clin Pharmacol*. 2021;87(6):2428-43. Available from: <https://doi.org/10.1111/bcp.14275>.
38. Marchetti M, Rivela P, Bertassello C, Canicatti M. Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. *J Clin Med*. 2022;11(7). Available from: <https://doi.org/10.3390/jcm11071868>.
39. Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R, et al. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. *Front Oncol*. 2021;11. Available from: <https://doi.org/10.3389/fonc.2021.698607>.
40. Messori A, Chiumente M, Mengato D. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data. *Clin Ther*. 2022;44(12):1626-32. Available from: <https://doi.org/10.1016/j.clinthera.2022.11.002>.
41. Newman NJ, Yu-Wai-Man P, Carelli V, Biousse V, Moster ML, Vignal-Clermont C, et al. Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A ND4 Mutation: Systematic Review and Indirect Comparison. *Front Neurol*. 2021;12:662838. Available from: <https://doi.org/10.3389/fneur.2021.662838>.
42. Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. *Hematology*. 2022;27(1):343-52. Available from: <https://doi.org/10.1080/16078454.2022.2045724>.
43. Papadouli I, Mueller-Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, et al. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. *Oncologist*. 2020;25(10):894-902. Available from: <https://doi.org/10.1634/theoncologist.2019-0646>.
44. Pascual-Morena C, Cavero-Redondo I, Luceron-Lucas-Torres M, Martinez-Garcia I, Rodriguez-Gutierrez E, Martinez-Vizcaino V. Onasemnogene abeparvovec in type 1 spinal muscular atrophy: A systematic review and meta-analysis. *Hum Gene Ther*. 2022. Available from: <https://doi.org/10.1089/hum.2022.161>.
45. Pasqui DM, Latorraca C, Pacheco RL, Riera R. CAR-T cell therapy for patients with hematological malignancies. A systematic review. *Eur J Haematol*. 2022;109(6):601-18. Available from: <https://doi.org/10.1111/ejh.13851>.

46. Petrou P. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. *Expert Rev Pharmacoecon Outcomes Res.* 2019;19(5):529-36. Available from: <https://doi.org/10.1080/14737167.2019.1651646>.
47. Pinho-Gomes AC, Cairns J. Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review. *Pharmacoecon Open.* 2022;6(2):147-67. Available from: <https://doi.org/10.1007/s41669-021-00295-2>.
48. Portuguese AJ, Gauthier J, Tykodi SS, Hall ET, Hirayama AV, Yeung CCS, et al. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. *Bone Marrow Transplant.* 2022. Available from: <https://doi.org/10.1038/s41409-022-01907-z>.
49. Raimond V, Kaltenbach E, Adam C, Lazzarotto S, Le Gales C, Perrier L, et al. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health. *Bull Cancer.* 2021;108(12):1162-9. Available from: <https://doi.org/10.1016/j.bulcan.2021.09.001>.
50. Ribero VA, Daigl M, Martí Y, Gorni K, Evans R, Scott DA, et al. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. *J Comp Eff Res.* 2022;11(5):347-70. Available from: <https://doi.org/10.2217/cer-2021-0216>.
51. Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. *J Hematol Oncol.* 2020;13(1):164. Available from: <https://doi.org/10.1186/s13045-020-01001-1>.
52. Salloum A, Koblinski J, Bazzi N, Zeitouni NC. Talimogene Laherparepvec in Non-Melanoma Cancers. *J Clin Aesthet Dermatol.* 2021;14(11):18-25.
53. Shah N, Sussman M, Crivera C, Valluri S, Benner J, Jagannath S. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations. *Clin Drug Investig.* 2021;41(3):201-10. Available from: <https://doi.org/10.1007/s40261-021-01012-x>.
54. Sharma A, Easow Mathew M, Sriganesh V, Reiss UM. Gene therapy for haemophilia. *Cochrane Database Syst Rev.* 2020;4(4):CD010822. Available from: <https://doi.org/10.1002/14651858.CD010822.pub4>.
55. Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. *Front Immunol.* 2022;13:1001263. Available from: <https://doi.org/10.3389/fimmu.2022.1001263>.
56. Soldozy S, Mulligan KM, Zheng DX, Levoska MA, Cullison CR, Elarjani T, et al. Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm? *Brain Sci.* 2021;11(10). Available from: <https://doi.org/10.3390/brainsci11101260>.
57. South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis((R)) for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. *Pharmacoecon Open.* 2019;3(2):151-61. Available from: <https://doi.org/10.1007/s41669-018-0102-3>.
58. Stahlie EHA, Mulder E, Reijers S, Balduzzi S, Zuur CL, Klop WMC, et al. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. *Crit Rev Oncol Hematol.* 2022;175:103705. Available from: <https://doi.org/10.1016/j.critrevonc.2022.103705>.
59. Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. *Ann Pharmacother.* 2020;54(10):1001-9. Available from: <https://doi.org/10.1177/1060028020914274>.
60. Sun Z, Liu M. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. *Cytotherapy.* 2022;24(9):940-53. Available from: <https://doi.org/10.1016/j.jcyt.2022.03.009>.
61. Thuresson PO, Vander Velde N, Gupta P, Talbot J. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. *Adv Ther.* 2020;37(12):4877-93. Available from: <https://doi.org/10.1007/s12325-020-01507-7>.
62. Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics.* 2019;37(10):1209-17. Available from: <https://doi.org/10.1007/s40273-019-00799-0>.
63. Wright FC, Kellett S, Hong NJL, Sun AY, Hanna TP, Nessim C, et al. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. *Curr Oncol.* 2020;27(3):e318-e25. Available from: <https://doi.org/10.3747/co.27.6523>.

64. Wu X, Zhang X, Xun R, Liu M, Sun Z, Huang J. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review. *Front Immunol.* 2021;12:693200. Available from: <https://doi.org/10.3389/fimmu.2021.693200>.
65. Xie R, Bi X, Shang B, Zhou A, Shi H, Shou J. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. *Viol J.* 2021;18(1):158. Available from: <https://doi.org/10.1186/s12985-021-01630-z>.
66. Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, et al. Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy. *Adv Ther.* 2022;39(5):1915-58. Available from: <https://doi.org/10.1007/s12325-022-02089-2>.
67. Ying Z, Song Y, Zhu J. Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2022;13:834113. Available from: <https://doi.org/10.3389/fphar.2022.834113>.
68. Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, et al. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. *Ann Med.* 2021;53(1):1547-59. Available from: <https://doi.org/10.1080/07853890.2021.1970218>.
69. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol.* 2009;62(10):1013-20. Available from: <https://doi.org/10.1016/j.jclinepi.2008.10.009>.
70. Bisailon R, Mombo NN, Beha S, Brouard ME, Arbour S, Béland M. Avis: tisagenlecleucel pour le traitement de la leucémie lymphoblastique aiguë récidivante ou réfractaire. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: <https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucel-pour-le-traitement-de-la-leucemie-lymphoblastique-aigue-recidivante-ou-refractaire.html>.
71. Bujold M, David I, Tessier A, Toupin I. État des connaissances: Efficacité et innocuité de l'onasemnogène abéparavec, du nusinersen et du risdiplam dans le traitement de l'amyotrophie spinale 5q. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2021. Available from: <https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/evaluation-de-la-pertinence-du-depistage-neonatal-de-lamyotrophie-spinale.html>.
72. Cadth. Axicabtagene ciloleucel for adults with relapsed or refractory large B-cell lymphoma. Canadian Agency for Drugs and Technologies in Health 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; requests@cadth.ca Canada Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019. Available from: <https://cadth.ca/sites/default/files/pdf/car-t/ct0002-clinical-report-redacted.pdf>.
73. Cadth. Tisagenlecleucel (Kymriah) for pediatric acute lymphoblastic leukemia and diffuse large b-cell lymphoma. Canadian Agency for Drugs and Technologies in Health 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; requests@cadth.ca Canada Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019. Available from: https://cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-clinical-report_jan2019.pdf.
74. de boer J, Wijma S. Advice on the reassessment of axicabtagene ciloleucel (Yescarta®). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: <https://english.zorginstituutnederland.nl/publications/reports/2021/07/26/advice-on-the-reassessment-of-axicabtagene-ciloleucel-yescarta>.
75. Erdos J, Sehic O, Wild C. ≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies. Austrian Institute for Health Technology Assessment Garnisonsgasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian

- Institute for Health Technology Assessment (AIHTA); 2021. Available from: https://eprints.aihta.at/1352/1/Policy%20Brief_001_1st%20Update.pdf.
76. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (diffuses großzelliges B-ZellLymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2018. Available from: https://www.iqwig.de/download/G18-10_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 77. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (akute lymphatische B-ZellLeukaemie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2018. Available from: https://www.iqwig.de/download/G18-11_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 78. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Voretigen Neparvovec (erblische Netzhautdystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G19-10_Voretigen-Neparvovec_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 79. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (primaer mediastinales großzelliges B-Zell-Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G18-18_Axicabtagen-Ciloleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 80. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G18-18_Axicabtagen-Ciloleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 81. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Konzept fuer eine anwendungsbegleitende Datenerhebung. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/a20-61_anwendungsbegleitende-datenerhebung-onasemnogen-abeparvovec_rapid-report_v1-0.pdf.
 82. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparvovec (5q-assozierte spinale Muskelatrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/g20-12_onasemnogen-abeparvovec_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
 83. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (diffuses großzelliges B-Zell-Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/G20-05_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.
 84. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (akute lymphatische B-Zell-Leukaemie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/G20-04_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf.

85. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Anwendungsbegleitende Datenerhebung zu Onasemnogen-Abeparvovec. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-149_abd-onasemnogen-abeparvovec-pruefung-protokoll-sap_addendum-zum-auftrag-a20-61_v1-0.pdf.
86. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparvovec (spinale Muskelatrophie) - Addendum zum Auftrag A21-68. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-128_onasemnogen-abeparvovec_addendum-zum-auftrag-a21-68_v1-0.pdf.
87. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Anwendungsbegleitende Datenerhebung zu Onasemnogen-Abeparvovec: Prüfung des Studienprotokolls und des statistischen Analyseplans Addendum zum Auftrag A20-61. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-107_anwendungsbegleitende-datenerhebung-onasemnogen-abeparvovec-pruefung-protokoll-und-sap_addendum-zum-auftrag-a20-61_v1-0.pdf.
88. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparvovec (spinale Muskelatrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-68_onasemnogen-abeparvovec_nutzenbewertung-35a-sgb-v_v1-0.pdf.
89. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Atidarsagen autotemcel / OTL-200 (metachromatische Leukodystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/g21-16_atidarsagen-autotemcel-otl-200_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
90. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (follikulaeres Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-23_tisagenlecleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
91. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom und primaer mediastinales großzelliges B-Zell-Lymphom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V (Ablauf Befristung). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-19_axicabtagen-ciloleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
92. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Voretigen Neparvovec (erbliche Netzhautdystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-09_voretigen-neparvovec_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
93. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Konzept fuer eine anwendungsbegleitende Datenerhebung - Brexucabtagen autoleucel. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im

- Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/a21-130_anwendungsbegleitende-datenerhebung-brexucabtagen-autoleucler_rapid-report_v1-0.pdf.
94. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Idcabtagen vicleucler (multiples Myelom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-01_idcabtagen-vicleucler_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf.
 95. Institute for C, Economic R. Valoctocogene roxaparvec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Institute for Clinical and Economic Review 101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414 info@icer-review.org United States United States: Institute for Clinical and Economic Review (ICER); 2020. Available from: <https://icer.org/assessment/hemophilia-a-2020/#timeline>.
 96. Institute for C, Economic R. Betibeglogene autotemcel for beta thalassemia: effectiveness and value. Institute for Clinical and Economic Review 101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414 info@icer-review.org United States United States: Institute for Clinical and Economic Review (ICER); 2022. Available from: <https://icer.org/beta-thalassemia-2022/#timeline>.
 97. Mengarelli C, Pichon-Riviere A, Alfie V, Argento F, García Martí S, Ciapponi A, et al. Risdiplam en atrofia muscular espinal. Institute for Clinical Effectiveness and Health Policy Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA info@iecs.org.ar Argentina Argentina: Institute for Clinical Effectiveness and Health Policy (IECS); 2021. Available from: <https://www.iecs.org.ar/publicacion/?id=20714>.
 98. Mombo NN, Bisailon R, Beha S, Brouard ME, Arbour S, Béland M. Avis: tisagenlecleucler pour le traitement du lymphome diffus à grandes cellules B récidivant ou réfractaire. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: <https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucler-pour-le-traitement-du-lymphome-diffus-a-grandes-cellules-b-recidivant-ou-refractaire.html>.
 99. N'Diaye Mombo N, Martin P, Beha S, Arbour S, Nshimyumukiza L. Avis: axicabtagene ciloleucler pour le traitement des lymphomes à grandes cellules B récidivants ou réfractaires. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: <https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-laxicabtagene-ciloleucler-pour-le-traitement-des-lymphomes-a-grandes-cellules-b-recidivants-ou-refractaires.html>.
 100. National Health Care I. Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zin.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: <https://english.zorginstituutnederland.nl/publications/reports/2021/07/21/package-advice-on-betibeglogene-autotemcel-zynteglo>.
 101. Panhuber A, Titieni-Schuhmann A, Goetz G, Wild C. CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: https://eprints.aihta.at/1415/1/HTA-Projektbericht_Nr.146.pdf.
 102. Sehic O, Wild C. ATMPs and gene therapies in development. Horizon scanning – update 2022. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: https://eprints.aihta.at/1383/1/Policy%20Brief_006b_1st%20Update.pdf.
 103. Sehic O, Wild C. CAR-T Zell-Therapien in Entwicklung, Update 2022. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria:

- Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: http://eprints.aihta.at/1368/1/Policy%20Brief_006a_1st%20Update.pdf.
104. Smc. Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. Scottish Medicines Consortium (SMC) Delta House | 50 West Nile Street susan.downie3@nhs.scot Susan Downie Scotland, United Kingdom Scotland, United Kingdom: Scottish Medicines Consortium (SMC); 2021. Available from: <https://www.scottishmedicines.org.uk/medicines-advice/onasemnogene-abeparvovec-zolgensma-full-smc2311/>.
 105. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Voretigen Neparvovec. The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3984/2019-10-17_AM-RL-XII_Voretigen%20Neparvovec_D-436_EN.pdf.
 106. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Axicabtagen-ciloleucel (PMBCL). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3772/2019-05-02_AM-RL-XII_Axicabtagen-Ciloleucel_D-406_D-416_EN.pdf.
 107. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Axicabtagen-ciloleucel. AWG A: rezidiviertes oder refraktäres diffus großzelliges B-Zell-Lymphom (DLBCL) AWG B: rezidiviertes oder refraktäres primär mediastinales B-Zell-Lymphom (PMBCL). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3771/2019-05-02_AM-RL-XII_Axicabtagen-Ciloleucel_D-406_D-416_EN.pdf.
 108. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Tisagenlecleucel (neubewertung nach fristablauf: diffus großzelliges B-zell-lymphom). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2020. Available from: https://www.g-ba.de/downloads/39-1464-4456/2020-09-17_AM-RL-XII_Tisagenlecleucel-DLBCL_D-530_EN.pdf.
 109. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Betibeglogene autotemcel (β -thalassämie) – terapiiekosten. The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2020. Available from: https://www.g-ba.de/downloads/39-1464-4291/2020-05-14_AM-RL-XII_Betibeglogene-autotemcel_D-497_EN.pdf.
 110. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Autologe anti-CD19-transduzierte CD3-positive zellen (mantelzell-lymphom, vorbehandelte atienten). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2021. Available from: https://www.g-ba.de/downloads/39-1464-4964/2021-08-05_AM-RL-XII_Autologe-Anti-CD19-transduzierte-CD3-positive-Zellen_D-633_EN.pdf.
 111. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Atidarsagen autotemcel (metachromatische leukodystrophie mit biallelischer mutation im ARSA-Gen). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2021. Available from: https://www.g-ba.de/downloads/39-1464-5103/2021-11-04_AM-RL-XII_Atidarsagen-autotemcel_D-678_EN.pdf.
 112. van der Waal JM, Wijma S. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA. The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: <https://english.zorginstituutnederland.nl/publications/reports/2021/05/06/package-advice-package-lock-medicinal-product-onasemnogene-abeparvovec-zolgensma>.
 113. Wijma S, de Boer JE. Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon

- Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2020. Available from: <https://english.zorginstituutnederland.nl/publications/reports/2020/02/17/voretigene-neparvovec-luxturna>.
114. Wild C. Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2020. Available from: http://eprints.aihta.at/1228/1/Policy_Brief_001.pdf.
 115. Wohlföhner K, Wild C. (Good) practice organisational models using real-world evidence for public funding of high priced therapies. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2021. Available from: https://eprints.aihta.at/1329/1/HTA-Projektbericht_Nr.138%20.pdf.
 116. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31886962>.
 117. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790160>.
 118. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790159>.
 119. Cadth. Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790158>.
 120. Cadth. Brexucabtagene Autoleucel (Tecartus). Canadian Journal of Health Technologies. 2021;1(11). Available from: <https://doi.org/10.51731/cjht.2021.187>.
 121. Cadth. Clinical Review Report, Voretigene Neparvovec (Luxturna): The Canadian Agency for Drugs and Technologies in Health (CADTH); 2021. Cadth common drug review. [accessed 19 Jan 2023]. Available from: <https://www.cadth.ca/sites/default/files/cdr/clinical/sg0643-luxturna-clinical-review-report.pdf>.
 122. Cadth. Clinical Review Report, Onasemnogene Abeparvovec (Zolgensma): The Canadian Agency for Drugs and Technologies in Health (CADTH); 2021. Cadth common drug review. [accessed Jan 19 2023]. Available from: <https://www.cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-clinical-review-report.pdf>.
 123. Cadth. Idecabtagene Vicleucel (Abecma). Canadian Journal of Health Technologies. 2022;2(2). Available from: <https://doi.org/10.51731/cjht.2022.250>.
 124. Cadth. Lisocabtagene Maraleucel (Breyanzi). Canadian Journal of Health Technologies. 2022;2(10). Available from: <https://doi.org/10.51731/cjht.2022.461>.
 125. Cadth. Axicabtagene Ciloleucel and Tisagenlecleucel for Diffuse Large B-cell Lymphoma: The Canadian Agency for Drugs and Technologies in Health (CADTH); 2022. CADTH Reference List RB1607-000. [accessed Jan 19 2023]. Available from: <https://www.cadth.ca/sites/default/files/pdf/htis/2022/RB1607%20CAR%20T-cell%20for%20DLBCL%20Final.pdf>.
 126. Cadth. Axicabtagene ciloleucel (Yescarta) (DRAFT); 2023. [accessed Jan 19 2023]. Available from: <https://www.cadth.ca/axicabtagene-ciloleucel>.
 127. SBU. Nyföddhetscreening för spinal muskelatrofi (SMA). Stockholm: Statens beredning för medicinsk och social utvärdering (SBU); 2023. SBU Bereder 360. [accessed Jan 24 2023]. Available from: <https://www.sbu.se/360>.

Bilaga 1. Sökstrategier

Embase via Elsevier 2023-01-19

Söktermer	Antal träffar
Avancerade terapiläkemedel	
1. ('axicabtagene ciloleucel'/de OR 'axi cel':ti,ab,kw OR 'axi-cel':ti,ab,kw OR 'fkc 876':ti,ab,kw OR 'fkc876':ti,ab,kw OR 'kte c19':ti,ab,kw OR 'kte c19 car':ti,ab,kw OR ktec19:ti,ab,kw OR yescarta:ti,ab,kw OR 'voretigene neparvec'/de OR 'aav2 hrpe65v2':ti,ab,kw OR 'ltw 888':ti,ab,kw OR 'ltw888':ti,ab,kw OR luxturna:ti,ab,kw OR 'spk rpe65':ti,ab,kw OR 'tisagenlecleucel t'/de OR 'cart 19':ti,ab,kw OR cart19:ti,ab,kw OR 'ctl 019':ti,ab,kw OR ctl019:ti,ab,kw OR kymriah:ti,ab,kw OR 'lg 740':ti,ab,kw OR lg740:ti,ab,kw OR tisagenlecleucel:ti,ab,kw OR 'tisagenlecleucel t':ti,ab,kw OR 'betibeglogene autotemcel'/de OR 'beti cel':ti,ab,kw OR 'lentiglobin bb 305 (beta thalassemia)':ti,ab,kw OR 'lentiglobin bb305 (beta thalassemia)':ti,ab,kw OR zynteglo:ti,ab,kw OR 'onasemnogene abeparvec'/de OR 'avxs 101':ti,ab,kw OR avxs101:ti,ab,kw OR charisma:ti,ab,kw OR 'oav 101':ti,ab,kw OR oav101:ti,ab,kw OR 'onasemnogene abeparvec xioi':ti,ab,kw OR 'onasemnogene abeparvec-xioi':ti,ab,kw OR zolgensma:ti,ab,kw OR 'atidarsagene autotemcel'/de OR 'gsk 2696274':ti,ab,kw OR gsk2696274:ti,ab,kw OR libmeldy:ti,ab,kw OR 'otl 200':ti,ab,kw OR otl200:ti,ab,kw OR 'idecabtagene vicleucel'/de OR abecma:ti,ab,kw OR 'bb 2121':ti,ab,kw OR bb2121:ti,ab,kw OR 'ide-cel':ti,ab,kw OR 'brexucabtagene autoleucel'/de OR 'brexu cel':ti,ab,kw OR 'brexu-cel':ti,ab,kw OR 'kte x19':ti,ab,kw OR 'kte x19 car':ti,ab,kw OR ktex19:ti,ab,kw OR 'ktex19 car':ti,ab,kw OR ktex19car:ti,ab,kw OR tecartus:ti,ab,kw OR 'valoctocogene roxaparvec'/de OR 'bmn 270':ti,ab,kw OR bmn270:ti,ab,kw OR roctavian:ti,ab,kw OR 'ciltacabtagene autoleucel'/de OR carvykti:ti,ab,kw OR 'cilta-cel':ti,ab,kw OR 'jnj 4528':ti,ab,kw OR 'jnj 68284528':ti,ab,kw OR jnj4528:ti,ab,kw OR jnj68284528:ti,ab,kw OR 'lcar-b38m':ti,ab,kw OR 'eladocogene exuparvec'/de OR 'aav2 haadc':ti,ab,kw OR 'aav2-haadc':ti,ab,kw OR 'agil aadc':ti,ab,kw OR 'agil-aadc':ti,ab,kw OR 'av 201':ti,ab,kw OR av201:ti,ab,kw OR 'gz 404477':ti,ab,kw OR gz404477:ti,ab,kw OR upstaza:ti,ab,kw OR 'vy aadc':ti,ab,kw OR 'lisocabtagene maraleucel'/de OR breyanzi:ti,ab,kw OR 'jcar 017':ti,ab,kw OR 'jcar 17':ti,ab,kw OR jcar017:ti,ab,kw OR jcar17:ti,ab,kw OR 'liso-cel':ti,ab,kw OR 'etranacogene dezaparvec'/de OR 'amt 061':ti,ab,kw OR amt061:ti,ab,kw OR 'csl 222':ti,ab,kw OR csl222:ti,ab,kw OR etranadez:ti,ab,kw OR 'alipogene tiparvec'/de OR 'aav1 lpls447x':ti,ab,kw OR 'amt 011':ti,ab,kw OR amt011:ti,ab,kw OR glybera:ti,ab,kw OR 'talimogene laherparepvec'/de OR 'amg 678':ti,ab,kw OR amg678:ti,ab,kw OR imlygic:ti,ab,kw OR oncovex:ti,ab,kw OR 'oncovex gm csf':ti,ab,kw OR 't vec':ti,ab,kw OR 'talminogene laherparepvec':ti,ab,kw OR 'lenadogene nolparvec'/de OR 'gs 010':ti,ab,kw OR gs010:ti,ab,kw	7 588
Genterapi i allmänhet i kombination med utvalda sjukdomar	
2. ('gene transfer method'/exp OR 'gene therapy'/exp OR 'gene therapy agent'/exp OR ((gene* NEAR/3 (repair* OR replac* OR therap* OR transfer OR vector*)):ti,ab,kw)) AND ('diffuse large b cell lymphoma'/exp OR 'follicular lymphoma'/exp OR 'inherited retinal dystrophy'/de OR 'acute b-cell leukemia cell line'/exp OR 'beta thalassemia'/exp OR 'spinal muscular atrophy'/exp OR 'metachromatic leukodystrophy'/de OR 'multiple myeloma'/exp OR 'mantle cell lymphoma'/de OR 'lymphatic leukemia'/exp OR 'hemophilia a'/de OR 'severe combined immunodeficiency'/exp OR 'hemophilia b'/de OR 'hyperlipoproteinemia type 1'/de OR 'melanoma'/exp OR 'leber hereditary optic neuropathy'/de)	25 406
Kombinerade sökblock	
3. 1 or 2	29 068
Sökfilter för systematiska översikter	
4. ('systematic review'/de OR 'meta analysis'/de OR [cochrane review]/lim OR 'biomedical technology assessment'/de OR ((systematic* NEAR/4 review*):ti,ab) OR ((systematic* NEAR/4 bibliographic*):ti,ab) OR ((systematic* NEAR/4 literature):ti,ab) OR	815 899

((comprehensive* NEAR/4 literature):ti,ab) OR ((comprehensive* NEAR/4 bibliographic*):ti,ab) OR ((integrative NEAR/4 review):ti,ab) OR 'meta analy*':ti,ab OR metaanaly*':ti,ab OR ((information NEAR/3 synthesis):ti,ab) OR ((data NEAR/3 synthesis):ti,ab) OR ((data NEAR/3 extract*):ti,ab) OR medline:ti,ab OR pubmed:ti,ab OR psyclit:ti,ab OR cinahl:ti,ab OR (psycinfo:ti,ab NOT 'psycinfo database':ti,ab) OR 'web of science':ti,ab OR scopus:ti,ab OR embase:ti,ab OR 'systematic overview*':ti OR 'systemic review*':ti OR 'scoping review':ti OR 'scoping literature review':ti OR 'mapping review':ti OR 'umbrella review*':ti OR 'review of reviews':ti OR 'overview of reviews':ti OR 'meta quantitative review*':ti OR 'integrative overview':ti OR 'meta synthesis':ti OR metasynthesis:ti OR 'quantitative review':ti OR 'quantitative synthesis':ti OR 'meta ethnography':ti OR 'research synthesis':ti OR 'systematic literature search':ti OR 'systematic literature research':ti OR 'evidence-based review':ti OR 'evidence synthesis':ti OR 'research overview*':ti,ab OR 'collaborative review*':ti,ab OR 'collaborative overview*':ti,ab OR 'technology assessment*':ti,ab OR 'technology overview*':ti,ab OR 'technology appraisal*':ti,ab OR hta:ti,ab OR htas:ti,ab OR 'methodological overview*':ti,ab OR 'methodologic overview*':ti,ab OR 'methodological review*':ti,ab OR 'methodologic review*':ti,ab OR 'quantitative overview*':ti,ab) NOT ('case report'/de OR 'editorial'/it OR 'letter'/it OR 'note'/it)

Kombinerade sökblock		
5.	3 AND 4	808
6.	5 AND (2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py)	575
Slutresultat		
7.		575

/de = kontrollerad term från EMTREE; **/exp** = kontrollerad term från EMTREE som inkluderar underliggande term(er); **:ab** = artikelsammanfattning; **:kw** = författarens nyckelord; **:ti** = artikeltitel; ***** = trunkering (sökning på ordstam); **' '** = frassökning; **NEAR/n** = närhetsoperator som fångar termer inom (n) antal ord

International HTA Database 2023-01-19

Söktermer	Antal träffar
Avancerade terapiläkemedel	
1. All = onasemnogene OR zolgensma OR axicabtagene OR yescarta OR tisagenlecleucel OR kymriah OR voretigene OR luxturna OR betibeglogene OR zynteglo OR atidarsagene OR libmeldy OR idecabtagene OR abecma OR brexucabtagene OR tecartus OR valoctocogene OR roctavian OR ciltacabtagene OR carvykti OR strimvelis OR eladocogene OR upstaza OR etranacogene OR etranadez OR alipogene OR glybera OR talimogene OR imlygic OR lenadogene OR lumevoq OR lisocabtagene OR breyanzi OR "gene therapy" OR amtp OR amtps	68
Kombinerade sökblock	
2. 1 AND Year: 2018–2023	46
Slutresultat	
3.	46

Bilaga 2. Inkluderade referenser

Inkluderad referens	Diagnos	Produkt	Produkttyp
Hematologiska tumörer			
1. Marchetti M, Rivela P, Bertassello C, Canicatti M. Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. <i>J Clin Med.</i> 2022;11(7). Available from: https://doi.org/10.3390/jcm11071868 .	B-cell chronic lymphocytic leukemia (CLL)		ATMP
2. Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R, et al. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucl, Tisagenlecleucl, and Lisocabtagene Maraleucl for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. <i>Front Oncol.</i> 2021;11. Available from: https://doi.org/10.3389/fonc.2021.698607	Hematological Malignancies	Axicabtagene Ciloleucl, Tisagenlecleucl, and Lisocabtagene Maraleucl	CAR T
3. Al-Mansour M, Al-Foheidi M, Ibrahim E. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis. <i>Mol Clin Oncol.</i> 2020;13(4):33. Available from: https://doi.org/10.3892/mco.2020.2103	Diffuse large B-cell lymphoma		CAR T
4. Sun Z, Liu M. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. <i>Cytotherapy.</i> 2022;24(9):940-53. Available from: https://doi.org/10.1016/j.jcyt.2022.03.009	Diffuse large B-cell lymphoma		CAR T
5. Efficace F, Cannella L, Sparano F, Giesinger JM, Vignetti M, Baron F, et al. Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. <i>Hemasphere.</i> 2022;6(12):e802. Available from: https://doi.org/10.1097/HS9.0000000000000802	Hematological Malignancies		CAR T
6. Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, et al. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. <i>Hemasphere.</i> 2021;5(2):e524. Available from: https://doi.org/10.1097/HS9.0000000000000524	Hematological Malignancies		CAR T
7. Pasqui DM, Latorraca C, Pacheco RL, Riera R. CAR-T cell therapy for patients with hematological malignancies. A systematic review. <i>Eur J Haematol.</i> 2022;109(6):601-18. Available from: https://doi.org/10.1111/ejh.13851	Hematological Malignancies		CAR T
8. Anderson MK, Torosyan A, Halford Z. Brexucabtagene Autoleucl: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. <i>Ann Pharmacother.</i> 2022;56(5):609-19. Available from: https://doi.org/10.1177/10600280211026338	Mantle Cell Lymphoma		CAR T
9. Gye A, Goodall S, De Abreu Lourenco R. A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. <i>Value Health.</i> 2022;25(1):47-58. Available from: https://doi.org/10.1016/j.jval.2021.07.008	Pediatric Acute Lymphoblastic Leukemia (ALL) and Adult Diffuse Large B-cell Lymphoma (DLBCL)		CAR T
10. George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, et al. Emerging Targets and Cellular	Relapsed or Refractory		CAR T

Inkluderad referens	Diagnos	Produkt	Produkttyp
Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clin Lymphoma Myeloma Leuk. 2021;21(11):741-51. Available from: https://doi.org/10.1016/j.clml.2021.06.003	Multiple Myeloma		
11. Li J, Tang Y, Huang Z. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials. Transl Cancer Res. 2022;11(3):569-79. Available from: https://doi.org/10.21037/tcr-22-344	Relapsed or Refractory Multiple Myeloma		CAR T
12. Messori A, Chiumente M, Mengato D. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data. Clin Ther. 2022;44(12):1626-32. Available from: https://doi.org/10.1016/j.clinthera.2022.11.002	Relapsed or Refractory large B-cell lymphoma (LBCL)		CAR T
13. Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, et al. Meta-analysis of ciltacabtagene autoleucl versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2022;38(10):1759-67. Available from: https://doi.org/10.1080/03007995.2022.2100651	Relapsed or Refractory Multiple Myeloma	ciltacabtagene autoleucl	CAR T (anti-BCMA)
14. Shah N, Sussman M, Crivera C, Valluri S, Benner J, Jagannath S. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations. Clin Drug Investig. 2021;41(3):201-10. Available from: https://doi.org/10.1007/s40261-021-01012-x	multiple myeloma	ciltacabtagene autoleucl and idecabtagene vicleucl	CAR T (anti-BCMA)
15. Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164. Available from: https://doi.org/10.1186/s13045-020-01001-1	multiple myeloma		CAR T (anti-BCMA)
16. Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, et al. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med. 2021;53(1):1547-59. Available from: https://doi.org/10.1080/07853890.2021.1970218	Relapsed or Refractory Multiple Myeloma		CAR T (anti-BCMA)
17. Papadouli I, Mueller-Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, et al. EMA Review of Axicabtagene Ciloleucl (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. Oncologist. 2020;25(10):894-902. Available from: https://doi.org/10.1634/theoncologist.2019-0646	Diffuse Large B-Cell Lymphoma	Axicabtagene Ciloleucl	CAR T (anti-CD19)
18. Halford Z, Anderson MK, Bennett LL. Axicabtagene Ciloleucl: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Ann Pharmacother. 2021;55(3):390-405. Available from: https://doi.org/10.1177/1060028020944233	Relapsed and Refractory Large B-cell Lymphoma	Axicabtagene Ciloleucl	CAR T (anti-CD19)
19. Wu X, Zhang X, Xun R, Liu M, Sun Z, Huang J. Efficacy and Safety of Axicabtagene Ciloleucl and Tisagenlecleucl Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review. Front Immunol. 2021;12:693200. Available from: https://doi.org/10.3389/fimmu.2021.693200	Lymphoma Patients With Secondary CNS Involvement	Axicabtagene Ciloleucl and Tisagenlecleucl	CAR T (anti-CD19)

Inkluderad referens	Diagnos	Produkt	Produkttyp
20. Portuguese AJ, Gauthier J, Tykodi SS, Hall ET, Hirayama AV, Yeung CCS, et al. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplant. 2022. Available from: https://doi.org/10.1038/s41409-022-01907-z	Post-transplant lymphoproliferative disorder (PTLD)	lisocabtagene maraleucel	CAR T (anti-CD19)
21. Halford Z, Anderson MK, Bennett LL, Moody J. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. Ann Pharmacother. 2021;55(4):466-79. Available from: https://doi.org/10.1177/1060028020948165	Acute Lymphoblastic Leukemia	Tisagenlecleucel	CAR T (anti-CD19)
22. Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019;37(10):1209-17. Available from: https://doi.org/10.1007/s40273-019-00799-0	Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia (ALL)	Tisagenlecleucel	CAR T (anti-CD19)
23. Petrou P. Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):529-36. Available from: https://doi.org/10.1080/14737167.2019.1651646		tisagenlecleucel and axicabtagene	CAR T (anti-CD19)
24. Raimond V, Kaltenbach E, Adam C, Lazzarotto S, Le Gales C, Perrier L, et al. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health. Bull Cancer. 2021;108(12):1162-9. Available from: https://doi.org/10.1016/j.bulcan.2021.09.001		tisagenlecleucel and axicabtagene ciloleucel	CAR T (anti-CD19)
25. Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Clin Lymphoma Myeloma Leuk. 2021;21(4):e334-e47. Available from: https://doi.org/10.1016/j.clml.2020.12.010	Acute Lymphoblastic Leukemia		CAR T (anti-CD19)
26. Cao JX, Gao WJ, You J, Wu LH, Liu JL, Wang ZX. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. Cytotherapy. 2019;21(7):769-81. Available from: https://doi.org/10.1016/j.jcyt.2019.04.005	Acute Lymphoblastic Leukemia		CAR T (anti-CD19)
27. Ying Z, Song Y, Zhu J. Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022;13:834113. Available from: https://doi.org/10.3389/fphar.2022.834113	Relapsed/Refractory Large B-Cell Lymphoma		CAR T (anti-CD19)
28. Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol. 2020;83(1):189-96. Available from: https://doi.org/10.1016/j.jaad.2020.01.039	Advanced Melanoma	talimogene laherparepvec	Onkolytiskt virus
29. Chen Z, Cheng Y, DeRemer D, Diaby V. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):923-41.	Hematological Malignancies		

Inkluderad referens	Diagnos	Produkt	Produkttyp
Available from: https://doi.org/10.1080/14737167.2021.1913056			
30. Thuresson PO, Vander Velde N, Gupta P, Talbot J. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Adv Ther.</i> 2020;37(12):4877-93. Available from: https://doi.org/10.1007/s12325-020-01507-7	Relapsed or Refractory Diffuse Large B Cell Lymphoma		
31. Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. <i>Hematology.</i> 2022;27(1):343-52. Available from: https://doi.org/10.1080/16078454.2022.2045724	Relapsed or Refractory Multiple Myeloma		
Övriga tumörer			
1. Stahlie EHA, Mulder E, Reijers S, Balduzzi S, Zuur CL, Klop WMC, et al. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. <i>Crit Rev Oncol Hematol.</i> 2022;175:103705. Available from: https://doi.org/10.1016/j.critrevonc.2022.103705	melanoma	Talimogene laherparepvec	Onkolytiskt virus
2. Soldozy S, Mulligan KM, Zheng DX, Levoska MA, Cullison CR, Elarjani T, et al. Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm? <i>Brain Sci.</i> 2021;11(10). Available from: https://doi.org/10.3390/brainsci11101260	melanoma brain metastases	Talimogene laherparepvec	Onkolytiskt virus
3. Salloum A, Koblinski J, Bazzi N, Zeitouni NC. Talimogene Laherparepvec in Non-Melanoma Cancers. <i>J Clin Aesthet Dermatol.</i> 2021;14(11):18-25.	Non-Melanoma Cancers	Talimogene laherparepvec	Onkolytiskt virus
4. Wright FC, Kellett S, Hong NJL, Sun AY, Hanna TP, Nessim C, et al. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. <i>Curr Oncol.</i> 2020;27(3):e318-e25. Available from: https://doi.org/10.3747/co.27.6523	satellite and in-transit metastasis (itm) from melanoma	Talimogene laherparepvec	Onkolytiskt virus
5. Lalu M, Leung GJ, Dong YY, Montroy J, Butler C, Auer RC, et al. Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review. <i>BMJ Open.</i> 2019;9(12):e029475. Available from: https://doi.org/10.1136/bmjopen-2019-029475		talimogene laherparepvec	Onkolytiskt virus
6. Xie R, Bi X, Shang B, Zhou A, Shi H, Shou J. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. <i>Virology.</i> 2021;18(1):158. Available from: https://doi.org/10.1186/s12985-021-01630-z	advanced or metastatic cancer		Onkolytiskt virus
7. Gao P, Ding G, Wang L. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. <i>Transl Cancer Res.</i> 2021;10(10):4290-302. Available from: https://doi.org/10.21037/tcr-21-905	intermediate to advanced solid tumors		Onkolytiskt virus
8. Cook M, Chauhan A. Clinical Application of Oncolytic Viruses: A Systematic Review. <i>Int J Mol Sci.</i> 2020;21(20):1-36. Available from: https://doi.org/10.3390/ijms21207505			Onkolytiskt virus
9. Li Z, Jiang Z, Zhang Y, Huang X, Liu Q. Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. <i>Cancers (Basel).</i>			Onkolytiskt virus

Inkluderad referens	Diagnos	Produkt	Produkttyp
2020;12(6). Available from: https://doi.org/10.3390/cancers12061416			
Genetisk ögonsjukdom			
1. Newman NJ, Yu-Wai-Man P, Carelli V, Biousse V, Moster ML, Vignal-Clermont C, et al. Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A ND4 Mutation: Systematic Review and Indirect Comparison. <i>Front Neurol.</i> 2021;12:662838. Available from: https://doi.org/10.3389/fneur.2021.662838	Genetisk ögonsjukdom, Leber hereditary optic neuropathy (LHON)		ATMP
2. Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, et al. Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal. <i>Pharmacoeconomics.</i> 2020;38(12):1309-18. Available from: https://doi.org/10.1007/s40273-020-00953-z	Genetisk ögonsjukdom	voretigene neparvovec	
3. Leroy BP, Fischer MD, Flannery JG, MacLaren RE, Dalkara D, Scholl HPN, et al. Gene therapy for inherited retinal disease: long-term durability of effect. <i>Ophthalmic Res.</i> 2022. Available from: https://doi.org/10.1159/000526317	Genetisk ögonsjukdom	voretigene neparvovec	
4. Burgess FR, Hall HN, Megaw R. Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease. <i>Asia Pac J Ophthalmol (Phila).</i> 2022;11(4):380-91. Available from: https://doi.org/10.1097/APO.0000000000000545	Genetisk ögonsjukdom		
5. Britten-Jones AC, Jin R, Gocuk SA, Cichello E, O'Hare F, Hickey DG, et al. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review. <i>Genet Med.</i> 2022;24(3):521-34. Available from: https://doi.org/10.1016/j.gim.2021.10.013			
Spinal muskeltrofi			
1. Baranello G, Gorni K, Daigl M, Kotzeva A, Evans R, Hawkins N, et al. Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy. <i>Clin Pharmacol Ther.</i> 2021;110(6):1435-54. Available from: https://doi.org/10.1002/cpt.2247	Spinal Muscular Atrophy	onasemnogene abeparvovec	
2. Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. <i>Orphanet J Rare Dis.</i> 2021;16(1):47. Available from: https://doi.org/10.1186/s13023-021-01695-7	Spinal Muscular Atrophy	onasemnogene abeparvovec	
3. Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. <i>Eur J Paediatr Neurol.</i> 2022;39:1-10. Available from: https://doi.org/10.1016/j.ejpn.2022.04.006	Spinal Muscular Atrophy	onasemnogene abeparvovec	
4. Pascual-Morena C, Cavero-Redondo I, Luceron-Lucas-Torres M, Martinez-Garcia I, Rodriguez-Gutierrez E, Martinez-Vizcaino V. Onasemnogene abeparvovec in type 1 spinal muscular atrophy: A systematic review and meta-analysis. <i>Hum Gene Ther.</i> 2022. Available from: https://doi.org/10.1089/hum.2022.161	Spinal Muscular Atrophy	onasemnogene abeparvovec	

Inkluderad referens	Diagnos	Produkt	Produkttyp
5. Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. <i>Ann Pharmacother.</i> 2020;54(10):1001-9. Available from: https://doi.org/10.1177/1060028020914274	Spinal Muscular Atrophy	Onasemnogene Abeparvovec	
6. Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, et al. Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy. <i>Adv Ther.</i> 2022;39(5):1915-58. Available from: https://doi.org/10.1007/s12325-022-02089-2	Spinal Muscular Atrophy		
7. Ribero VA, Daigl M, Martí Y, Gorni K, Evans R, Scott DA, et al. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. <i>J Comp Eff Res.</i> 2022;11(5):347-70. Available from: https://doi.org/10.2217/cer-2021-0216	spinal muscular atrophy		
Svår kombinerad immunbrist			
1. Böhnke A, Minartz C, Radeck-Knorre S, Schwenke C, Neubauer AS. Gene therapy for rare diseases: Differences to chronic therapy and example AADC-deficiency. <i>Gentherapie für seltene Erkrankungen: Unterschiede zu chronischer Therapie und Beispiel AADC-Mangel.</i> 2022;27(1):25-35. Available from: https://doi.org/10.1055/a-1629-7213	SCID	eladocagene exuparvovec	
2. South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis((R)) for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. <i>Pharmacocon Open.</i> 2019;3(2):151-61. Available from: https://doi.org/10.1007/s41669-018-0102-3	SCID	Strimvelis	
Hemofili			
1. Sharma A, Easow Mathew M, Sriganesh V, Reiss UM. Gene therapy for haemophilia. <i>Cochrane Database Syst Rev.</i> 2020;4(4):CD010822. Available from: https://doi.org/10.1002/14651858.CD010822.pub4	Hemofili		ATMP
Övrigt/Ospecificerat			
1. Pinho-Gomes AC, Cairns J. Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review. <i>Pharmacocon Open.</i> 2022;6(2):147-67. Available from: https://doi.org/10.1007/s41669-021-00295-2		talimogene laherparepvec, strimvelis, tisagenlecleucel, axicabtagene ciloleucel, voretigene neparvovec, autologous anti-CD19-transduced CD3+ cells, betibeglogene autotemcel, onasemnogene abeparvovec and OTL-200	Advanced Therapy Medicinal Products

Inkluderad referens	Diagnos	Produkt	Produkttyp
2. Horton RH, Saade D, Markati T, Harriss E, Bonnemann CG, Muntoni F, et al. A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment. J Neurol Neurosurg Psychiatry. 2022;93(12):1276-88. Available from: https://doi.org/10.1136/jnnp-2022-329431	neurology	AAV	ATMP
3. Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2021;87(6):2428-43. Available from: https://doi.org/10.1111/bcp.14275			ATMP
4. Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front Immunol. 2022;13:1001263. Available from: https://doi.org/10.3389/fimmu.2022.1001263		AAV	ATMP
5. Bhatt DK, Wekema L, Carvalho Barros LR, Chammas R, Daemen T. A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Mol Ther Oncolytics. 2021;23:239-53. Available from: https://doi.org/10.1016/j.omto.2021.09.008		talimogene laherparepvec	Onkolytiskt virus
6. Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, et al. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. Pharmacoeconomics. 2021;39(9):995-1019. Available from: https://doi.org/10.1007/s40273-021-01051-4			

Från INAHTA

1. Bisailon R, Mombo NN, Beha S, Brouard ME, Arbour S, Béland M. Avis: tisagenlecleucel pour le traitement de la leucémie lymphoblastique aiguë récidivante ou réfractaire. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucel-pour-le-traitement-de-la-leucemie-lymphoblastique-aigue-recidivante-ou-refractaire.html	tisagenlecleuce I		
2. Bujold M, David I, Tessier A, Toupin I. État des connaissances: Efficacité et innocuité de l'onasemnogène abéparavec, du nusinersen et du risdiplam dans le traitement de l'amyotrophie spinale 5q. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2021. Available from: https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/evaluation-de-la-pertinence-du-depistage-neonatal-de-lamyotrophie-spinale.html			
3. Cadth. Axicabtagene ciloleucel for adults with relapsed or refractory large B-cell lymphoma. Canadian Agency for Drugs and Technologies in Health 600-865 Carling Avenue,			

Inkluderad referens	Diagnos	Produkt	Produkttyp
Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; requests@cadth.ca Canada Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019. Available from: https://cadth.ca/sites/default/files/pdf/car-t/ct0002-clinical-report-redacted.pdf			
4. Cadth. Tisagenlecleucel (Kymriah) for pediatric acute lymphoblastic leukemia and diffuse large b-cell lymphoma. Canadian Agency for Drugs and Technologies in Health 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; requests@cadth.ca Canada Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019. Available from: https://cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-clinical-report_jan2019.pdf			
5. de boer J, Wijma S. Advice on the reassessment of axicabtagene ciloleucel (Yescarta®). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: https://english.zorginstituutnederland.nl/publications/reports/2021/07/26/advice-on-the-reassessment-of-axicabtagene-ciloleucel-yescarta			
6. Erdos J, Sehic O, Wild C. ≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2021. Available from: https://eprints.aihta.at/1352/1/Policy%20Brief_001_1st%20Update.pdf			
7. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (diffuses großzelliges B-ZellLymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2018. Available from: https://www.iqwig.de/download/G18-10_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf			
8. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (akute lymphatische B-ZellLeukaemie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2018. Available from: https://www.iqwig.de/download/G18-11_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf			

Inkluderad referens	Diagnos	Produkt	Produkttyp
<p>9. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Voretigen Neparovvec (erbliche Netzhautdystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G19-10_Voretigen-Neparovvec_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf</p>			
<p>10. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (primaer mediastinales großzelliges B-Zell-Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G18-18_Axicabtagen-Ciloleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf</p>			
<p>11. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2019. Available from: https://www.iqwig.de/download/G18-18_Axicabtagen-Ciloleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf</p>			
<p>12. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Konzept fuer eine anwendungsbegleitende Datenerhebung. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/a20-61_anwendungsbegleitende-datenerhebung-onasemnogen-abeparovvec_rapid-report_v1-0.pdf</p>			
<p>13. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparovvec (5q-assozierte spinale Muskelatrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/g20-12_onasemnogen-abeparovvec_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf</p>			
<p>14. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (diffuses großzelliges B-Zell-Lymphom).</p>			

Inkluderad referens	Diagnos	Produkt	Produkttyp
<p>Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/G20-05_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf</p>			
<p>15. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (akute lymphatische B-Zell-Leukaemie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2020. Available from: https://www.iqwig.de/download/G20-04_Tisagenlecleucel_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf</p>			
<p>16. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Anwendungsbegleitende Datenerhebung zu Onasemnogen-Abeparvovec. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-149_abd-onasemnogen-abeparvovec-pruefung-protokoll-sap_addendum-zum-auftrag-a20-61_v1-0.pdf</p>			
<p>17. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparvovec (spinale Muskelatrophie) - Addendum zum Auftrag A21-68. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-128_onasemnogen-abeparvovec_addendum-zum-auftrag-a21-68_v1-0.pdf</p>			
<p>18. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Anwendungsbegleitende Datenerhebung zu Onasemnogen-Abeparvovec: Prüfung des Studienprotokolls und des statistischen Analyseplans Addendum zum Auftrag A20-61. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-107_anwendungsbegleitende-datenerhebung-onasemnogen-abeparvovec-pruefung-protokoll-und-sap_addendum-zum-auftrag-a20-61_v1-0.pdf</p>			
<p>19. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Onasemnogen-Abeparvovec (spinale Muskelatrophie). Institute for Quality and Efficiency in Health Care (IQWiG)</p>			

Inkluderad referens	Diagnos	Produkt	Produkttyp
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/a21-68_onasemnogen-abeparvovec_nutzenbewertung-35a-sgb-v_v1-0.pdf			
20. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Atidarsagen autotemcel / OTL-200 (metachromatische Leukodystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2021. Available from: https://www.iqwig.de/download/g21-16_atidarsagen-autotemcel-otl-200_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf			
21. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Tisagenlecleucel (follikulaeres Lymphom). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-23_tisagenlecleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf			
22. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom und primaer mediastinales großzelliges B-Zell-Lymphom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V (Ablauf Befristung). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-19_axicabtagen-ciloleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf			
23. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Voretigen Neparvovec (erbliche Netzhautdystrophie). Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-09_voretigen-neparvovec_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf			
24. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Konzept fuer eine anwendungsbegleitende Datenerhebung - Brexucabtagen autoleucel. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany:			

Inkluderad referens	Diagnos	Produkt	Produkttyp
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/a21-130_anwendungsbegleitende-datenerhebung-brexcuabtagen-autoleucl_rapid-report_v1-0.pdf			
25. Institut fuer Qualitaet und Wirtschaftlichkeit im G. Idecabtagen vicleucl (multiples Myelom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V. Institute for Quality and Efficiency in Health Care (IQWiG) IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851 berichte@iqwig.de Germany Germany: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2022. Available from: https://www.iqwig.de/download/g22-01_idecabtagen-vicleucl_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf			
26. Institute for C, Economic R. Valoctocogene roxaparvec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Institute for Clinical and Economic Review 101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414 info@icer-review.org United States United States: Institute for Clinical and Economic Review (ICER); 2020. Available from: https://icer.org/assessment/hemophilia-a-2020/#timeline			
27. Institute for C, Economic R. Betibeglogene autotemcel for beta thalassemia: effectiveness and value. Institute for Clinical and Economic Review 101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414 info@icer-review.org United States United States: Institute for Clinical and Economic Review (ICER); 2022. Available from: https://icer.org/beta-thalassemia-2022/#timeline .			
28. Mengarelli C, Pichon-Riviere A, Alfie V, Argento F, García Martí S, Ciapponi A, et al. Risdiplam en atrofia muscular espinal. Institute for Clinical Effectiveness and Health Policy Dr. Emilio Ravnani 2024, Buenos Aires - Argentina, C1414 CABA info@iecs.org.ar Argentina Argentina: Institute for Clinical Effectiveness and Health Policy (IECS); 2021. Available from: https://www.iecs.org.ar/publicacion/?id=20714			
29. Mombo NN, Bisailon R, Beha S, Brouard ME, Arbour S, Béland M. Avis: tisagenlecleucl pour le traitement du lymphome diffus à grandes cellules B récidivant ou réfractaire. Institut national d'excellence en sante et en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-le-tisagenlecleucl-pour-le-traitement-du-lymphome-diffus-a-grandes-cellules-b-recidivant-ou-refractaire.html			
30. N'Diaye Mombo N, Martin P, Beha S, Arbour S, Nshimyumukiza L. Avis: axicabtagene ciloleucl pour le traitement des lymphomes à grandes cellules B récidivants ou réfractaires. Institut national d'excellence en sante et			

Inkluderad referens	Diagnos	Produkt	Produkttyp
<p>en services sociaux L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369 demande@inesss.qc.ca Canada Quebec Canada: Institut national d'excellence en sante et en services sociaux (INESSS); 2019. Available from: https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-laxicabtagene-ciloleucl-pour-le-traitement-des-lymphomes-a-grandes-cellules-b-recidivants-ou-refractaires.html</p>			
<p>31. National Health Care I. Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: https://english.zorginstituutnederland.nl/publications/rep-orts/2021/07/21/package-advice-on-betibeglogene-autotemcel-zynteglo</p>			
<p>32. Panhuber A, Titieni-Schuhmann A, Goetz G, Wild C. CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: https://eprints.aihta.at/1415/1/HTA-Projektbericht_Nr.146.pdf</p>			
<p>33. Sehic O, Wild C. ATMPs and gene therapies in development. Horizon scanning – update 2022. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: https://eprints.aihta.at/1383/1/Policy%20Brief_006b_1st%20Update.pdf</p>			
<p>34. Sehic O, Wild C. CAR-T Zell-Therapien in Entwicklung, Update 2022. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2022. Available from: http://eprints.aihta.at/1368/1/Policy%20Brief_006a_1st%20Update.pdf</p>			
<p>35. Smc. Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. Scottish Medicines Consortium (SMC) Delta House 50 West Nile Street susan.downie3@nhs.scot Susan Downie Scotland, United Kingdom Scotland, United Kingdom: Scottish Medicines Consortium (SMC); 2021. Available from: https://www.scottishmedicines.org.uk/medicines-</p>			

Inkluderad referens	Diagnos	Produkt	Produkttyp
advice/onasemnogene-abeparovvec-zolgensma-full-smc2311/			
36. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Voretigen Neparovvec. The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3984/2019-10-17_AM-RL-XII_Voretigen%20Neparovvec_D-436_EN.pdf			
37. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Axicabtagen-ciloleucel (PMBCL). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3772/2019-05-02_AM-RL-XII_Axicabtagen-Ciloleucel_D-406_D-416_EN.pdf			
38. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Axicabtagen-ciloleucel. AWG A: rezidivierendes oder refraktäres diffus großzelliges B-Zell-Lymphom (DLBCL) AWG B: rezidivierendes oder refraktäres primär mediastinales B-Zell-Lymphom (PMBCL). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2019. Available from: https://www.g-ba.de/downloads/39-1464-3771/2019-05-02_AM-RL-XII_Axicabtagen-Ciloleucel_D-406_D-416_EN.pdf			
39. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Tisagenlecleucel (neubewertung nach fristablauf: diffus großzelliges B-zell-lymphom). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2020. Available from: https://www.g-ba.de/downloads/39-1464-4456/2020-09-17_AM-RL-XII_Tisagenlecleucel-DLBCL_D-530_EN.pdf			
40. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Betibeglogene autotemcel (β-thalassämie) – terapiestrukturkosten. The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2020. Available from: https://www.g-ba.de/downloads/39-1464-4291/2020-05-14_AM-RL-XII_Betibeglogene-autotemcel_D-497_EN.pdf			
41. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Autologe anti-CD19-transduzierte CD3-positive zellen (mantelzell-lymphom, vorbehandelte atienten). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2021. Available from: https://www.g-ba.de/downloads/39-1464-			

Inkluderad referens	Diagnos	Produkt	Produkttyp
<p>4964/2021-08-05_AM-RL-XII_Autologe-Anti-CD19-transduzierte-CD3-positive-Zellen_D-633_EN.pdf</p>			
<p>42. The Federal Joint C. Arzneimittel-Richtlinie/Anlage XII: Atidarsagen autotemcel (metachromatische leukodystrophie mit biallelischer mutation im ARSA-Gen). The Federal Joint Committee Gutenbergstr. 13, 10587 Berlin, Germany Fachberatung-Medizin@g-ba.de Fachberatung Medizin [Department of Medical Consultancy] Germany Germany: The Federal Joint Committee (G-BA); 2021. Available from: https://www.g-ba.de/downloads/39-1464-5103/2021-11-04_AM-RL-XII_Atidarsagen-autotemcel_D-678_EN.pdf</p>			
<p>43. van der Waal JM, Wijma S. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA. The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2021. Available from: https://english.zorginstituutnederland.nl/publications/reports/2021/05/06/package-advice-package-lock-medicinal-product-onasemnogene-abeparvovec-zolgensma</p>			
<p>44. Wijma S, de Boer JE. Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice). The National Health Care Institute (ZIN, Zorginstituut Nederland) Postbus 320, NL-1110 AH Diemen The Netherlands TSibma@zinl.nl Timon Sibma The Netherlands The Netherlands: The National Health Care Institute (ZIN, Zorginstituut Nederland); 2020. Available from: https://english.zorginstituutnederland.nl/publications/reports/2020/02/17/voretigene-neparvovec-luxturna</p>			
<p>45. Wild C. Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2020. Available from: http://eprints.aihta.at/1228/1/Policy_Brief_001.pdf</p>			
<p>46. Wohlföhner K, Wild C. (Good) practice organisational models using real-world evidence for public funding of high priced therapies. Austrian Institute for Health Technology Assessment Garnisongasse 7/20, A-1090 Vienna, Austria office@aihta.at Austria Austria: Austrian Institute for Health Technology Assessment (AIHTA); 2021. Available from: https://eprints.aihta.at/1329/1/HTA-Projektbericht_Nr.138%20.pdf</p>			
<p>Från CADTH</p>			
<p>1. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31886962</p>			
<p>2. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations: Canadian Agency for Drugs and</p>			

Inkluderad referens	Diagnos	Produkt	Produkttyp
Technologies in Health; 2019. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790160			
3. Cadth. Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790159			
4. Cadth. Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=31790158			
5. Cadth. Brexucabtagene Autoleucel (Tecartus). Canadian Journal of Health Technologies. 2021;1(11). Available from: https://doi.org/10.51731/cjht.2021.187			
6. Cadth. Clinical Review Report, Voretigene Neparovec (Luxturna): The Canadian Agency for Drugs and Technologies in Health (CADTH); 2021. Cadth common drug review. [accessed 19 Jan 2023]. Available from: https://www.cadth.ca/sites/default/files/cdr/clinical/sg0643-luxturna-clinical-review-report.pdf			
7. Cadth. Clinical Review Report, Onasemnogene Apeparovec (Zolgensma): The Canadian Agency for Drugs and Technologies in Health (CADTH); 2021. Cadth common drug review. [accessed Jan 19 2023]. Available from: https://www.cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-clinical-review-report.pdf			
8. Cadth. Idecabtagene Vicleucel (Abecma). Canadian Journal of Health Technologies. 2022;2(2). Available from: https://doi.org/10.51731/cjht.2022.250			
9. Cadth. Lisocabtagene Maraleucel (Breyanzi). Canadian Journal of Health Technologies. 2022;2(10). Available from: https://doi.org/10.51731/cjht.2022.461			
10. Cadth. Axicabtagene Ciloleucel and Tisagenlecleucel for Diffuse Large B-cell Lymphoma: The Canadian Agency for Drugs and Technologies in Health (CADTH); 2022. CADTH Reference List RB1607-000. [accessed Jan 19 2023]. Available from: https://www.cadth.ca/sites/default/files/pdf/htis/2022/RB1607%20CAR%20T-cell%20for%20DLBCL%20Final.pdf			
11. Cadth. Axicabtagene ciloleucel (Yescarta) (DRAFT); 2023. [accessed Jan 19 2023]. Available from: https://www.cadth.ca/axicabtagene-ciloleucel			
Från SBU			
1. SBU. Nyföddhetscreening för spinal muskelatrofi (SMA). Stockholm: Statens beredning för medicinsk och social utvärdering (SBU); 2023. SBU Bereder 360. [accessed Jan 24 2023]. Available from: https://www.sbu.se/360			

Bilaga 3 Flödesschema för urval

